TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10541229

Group type: EXPERIMENTAL
Intervention: Selfotel (CGS 19755)
Number of subjects: 693

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 693
Study: 8024947

Group type: EXPERIMENTAL
Intervention: Single enantiomer formulation (SEF) of (S)-atenolol, 50 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Racemic mixture (Tenormin, TMN) of (R,S)-atenolol, 100 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Single enantiomer formulation (SEF) of (S)-atenolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Racemic mixture (Tenormin, TMN) of (R,S)-atenolol
Number of subjects: 8
Study: 2584565

Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 12
Study: 5823051

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives with low dose progestogen and high dose oestrogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential oral contraceptives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progestogenic combined preparations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oestrogenic sequential regimens and low-dose progestogen-only regimens
Number of subjects: 0
Study: 31846029

Group type: EXPERIMENTAL
Intervention: Audit and Feedback (A&F)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Audit and Feedback with Peer Norm Comparison
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (not exposed to either intervention)
Number of subjects: 37
Study: 30556470

Group type: EXPERIMENTAL
Intervention: Broad Brush Survey (BBS) approach
Number of subjects: 0
Study: 28737466

Group type: EXPERIMENTAL
Intervention: Homozygous mutant of rs1501299
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homozygous mutant of rs2241766
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homozygous mutant of rs7649121
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smokers with rs1501299-GT or TT genotype
Number of subjects: 0
Study: 26385346

Group type: EXPERIMENTAL
Intervention: Intranasal S. salivarius 24SMB
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Colonized children with S. salivarius 24SMB
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-colonized children
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Colonized children treated with antibiotics
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-colonized children treated with antibiotics
Number of subjects: 100
Study: 24217026

Group type: EXPERIMENTAL
Intervention: Capsule A containing artificial food colorings (AFCs)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Capsule B containing sodium benzoate
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 130
Study: 21472442

Group type: EXPERIMENTAL
Intervention: Participants perceived as belonging to the same group (ingroup) during the Simon task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants perceived as belonging to a different group (outgroup) during the Simon task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants experiencing positive interdependence during the Simon task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants experiencing negative interdependence during the Simon task
Number of subjects: 0
Study: 18838526

Group type: EXPERIMENTAL
Intervention: Low GI breakfast
Number of subjects: 21

Group type: COMPARATOR
Intervention: High GI breakfast
Number of subjects: 21
Study: 16426468

Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg 6 hourly
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12802822

Group type: EXPERIMENTAL
Intervention: Receiving dental care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not receiving dental care
Number of subjects: 0
Study: 11016670

Group type: EXPERIMENTAL
Intervention: Neomycin sulfate patch tests with various doses and vehicles
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Serial-dose series for time intervals ranging from 3 to 96 h
Number of subjects: 16

Group type: COMPARATOR
Intervention: Visual assessments
Number of subjects: 16
Study: 9177881

Group type: EXPERIMENTAL
Intervention: Anisodamine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no anisodamine)
Number of subjects: 14
Study: 8104509

Group type: EXPERIMENTAL
Intervention: Haloperidol (0.2 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol challenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Debrisoquin (peripheral monoamine oxidase inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study: 2425168

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (0.0125-0.50 micrograms/kg/min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hydralazine (0.05-0.3 mg/kg, bolus injections)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 18
Study: 29561783

Group type: EXPERIMENTAL
Intervention: MK7 (360 mcg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 26611780

Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius PS2 (9 log10 colony‐forming units daily from week 30 of pregnancy until delivery)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius PS2
Number of subjects: 108
Study: 24533064

Group type: EXPERIMENTAL
Intervention: H7N3 live attenuated influenza vaccine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23052711

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 187

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 187
Study: 19687293

Group type: EXPERIMENTAL
Intervention: Reboxetine (RBX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18504215

Group type: EXPERIMENTAL
Intervention: Recombinant human brain natriuretic peptide (rhBNP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 50
Study: 15944888

Group type: EXPERIMENTAL
Intervention: Feedback of the axial rotation moment to correct asymmetric efforts
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Chronic low back pain subjects
Number of subjects: 89

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Normalized EMG imbalance parameters
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: EMG imbalance parameters
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Low back status and pain location
Number of subjects: 89
Study: 12355220

Group type: EXPERIMENTAL
Intervention: Laparoscopic colorectal resection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional colorectal resection
Number of subjects: 30
Study: 10609635

Group type: EXPERIMENTAL
Intervention: Infrared-controlled computer interface using tongue-touch circuitry and low power laser (<0.1 mW) beam.
Number of subjects: 0
Study: 8941177

Group type: EXPERIMENTAL
Intervention: Demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Absorbable gelatine sponge (Gelfoam)
Number of subjects: 32
Study: 1837510

Group type: EXPERIMENTAL
Intervention: Half-sized lunch with reduced insulin dose
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Delayed evening meal
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control meal (normal meals)
Number of subjects: 43
Study: 7028238

Group type: EXPERIMENTAL
Intervention: Caffeine in low dose + Methylphenidate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Caffeine in low dose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High dose caffeine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo or no-drug conditions
Number of subjects: 6
Study: 30475722

Group type: EXPERIMENTAL
Intervention: Remind-to-Move (RTM) using wearable devices for three consecutive hours daily over four weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sham devices
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 84
Study: 28062537

Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Heart Failure Education
Number of subjects: 180
Study: 26958310

Group type: EXPERIMENTAL
Intervention: Web-based audit and feedback intervention with outreach visits
Number of subjects: 14847

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 14847
Study: 23663298

Group type: EXPERIMENTAL
Intervention: Shallow needle puncture method
Number of subjects: 600
Study: 20568955

Group type: EXPERIMENTAL
Intervention: Combined metformin-clomiphene citrate (CC)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Highly purified urinary FSH (HP-uFSH)
Number of subjects: 153
Study: 20014600

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion (20 ng kg(‐1) min(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (normal saline 0.9%)
Number of subjects: 30
Study: 17470271

Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 18
Study: 14756915

Group type: EXPERIMENTAL
Intervention: Dephytinised soya formula (<6 mg phytic acid/kg liquid formula)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Regular soya formula (300 mg phytic acid/kg liquid formula)
Number of subjects: 9
Study: 11716197

Group type: EXPERIMENTAL
Intervention: Asthma nurse intervention during hospitalization
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no asthma nurse intervention)
Number of subjects: 80
Study: 8986681

Group type: EXPERIMENTAL
Intervention: 2.5 mg/d tibolone (n = 15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Iron pill (placebo, n = 14)
Number of subjects: 29
Study: 8503809

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Flunitrazepam 1 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3552107

Group type: EXPERIMENTAL
Intervention: Jiggling allowed
Number of subjects: 21

Group type: COMPARATOR
Intervention: Jiggling not allowed
Number of subjects: 21
Study: 30474191

Group type: EXPERIMENTAL
Intervention: Diabetes with cirrhosis
Number of subjects: 154

Group type: COMPARATOR
Intervention: Diabetes without cirrhosis
Number of subjects: 154
Study: 30522667

Group type: EXPERIMENTAL
Intervention: Restore paclitaxel‐coated balloon (DCB)
Number of subjects: 230

Group type: COMPARATOR
Intervention: RESOLUTE Integrity drug-eluting stent (DES)
Number of subjects: 230
Study: 26849017

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 30° head up position
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 45° head up position
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Younger group (1-8 years)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Older group (9-16 years)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 120
Study: 24376274

Group type: EXPERIMENTAL
Intervention: JTT-751 (1.5 to 6.0 g/day)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Sevelamer hydrochloride (3.0 to 9.0 g/day)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: JTT-751
Number of subjects: 230

Group type: COMPARATOR
Intervention: Sevelamer hydrochloride
Number of subjects: 230
Study: 21984532

Group type: EXPERIMENTAL
Intervention: 12 weeks of twice weekly, 60-minute group exercise sessions, including mobility, balance and resistance exercises.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 32
Study: 20506062

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (INCB‐018424)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical cream formulation of Ruxolitinib
Number of subjects: 0
Study: 18397484

Group type: EXPERIMENTAL
Intervention: 8-week pegIFN-alpha-2a therapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 24-week pegIFN-alpha-2a therapy
Number of subjects: 55
Study: 15850095

Group type: EXPERIMENTAL
Intervention: Carpal tunnel release (CTR) surgery
Number of subjects: 0
Study: 12408198

Group type: EXPERIMENTAL
Intervention: Enhanced EFNEP intervention arm (Usual WIC Care plus a sustained, multi-component intervention including home visits, group classes and monthly telephone counseling)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (WIC nutrition and breastfeeding education)
Number of subjects: 0
Study: 10479202

Group type: EXPERIMENTAL
Intervention: Weanimix (W)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Weanimix plus vitamins and minerals (WM)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Weanimix plus fish powder (WF)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Koko plus fish powder (KF)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Non-intervention group (NI)
Number of subjects: 208
Study: 8569363

Group type: EXPERIMENTAL
Intervention: Horse-chestnut seed extract (HCSE, 50 mg aescin, twice daily)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Compression stockings class II
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 1722443

Group type: EXPERIMENTAL
Intervention: Islet amyloid polypeptide infusion (150 pmol min‐1 kg‐1)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Calcitonin infusion (50 pmol min‐1 kg‐1)
Number of subjects: 5
Study: 6180901

Group type: EXPERIMENTAL
Intervention: Triprolidine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of triprolidine and pseudoephedrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pseudoephedrine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triprolidine vs Combination
Number of subjects: 0
Study: 31952305

Group type: EXPERIMENTAL
Intervention: Past experiences in actively initiating DNR discussions with patients or patients’ families
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Age group 20.0 to 29.9 years
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Experiences of actively initiated DNR or LST discussions with patients’ families
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Experience in actively initiating discussions about LST withdrawal with patients’ families
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Being male and possessing an education level higher than university
Number of subjects: 132
Study: 30823945

Group type: EXPERIMENTAL
Intervention: Liraglutide combined with insulin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Insulin alone (Control)
Number of subjects: 92
Study: 27632846

Group type: EXPERIMENTAL
Intervention: BAPS rehabilitation program (3 times/week for 4 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 22
Study: 27117860

Group type: EXPERIMENTAL
Intervention: Posterior shoulder delivery
Number of subjects: 543

Group type: COMPARATOR
Intervention: Anterior shoulder delivery
Number of subjects: 543
Study: 25302456

Group type: EXPERIMENTAL
Intervention: 10 mL 1% lignocaine PPNB and 100 mg diclofenac suppository
Number of subjects: 96

Group type: COMPARATOR
Intervention: 10 mL 1% lignocaine PPNB and placebo suppository
Number of subjects: 96
Study: 21733663

Group type: EXPERIMENTAL
Intervention: citalopram 40 mg/lecozotan 10 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: citalopram 40 mg/placebo
Number of subjects: 43
Study: 19363437

Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg/d
Number of subjects: 51
Study: 17244282

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) 40 mg
Number of subjects: 261

Group type: COMPARATOR
Intervention: Bacillus Calmette-Guérin (BCG) 120 mg
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Bacillus Calmette-Guérin (BCG)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) and Bacillus Calmette-Guérin (BCG)
Number of subjects: 261
Study: 15838439

Group type: EXPERIMENTAL
Intervention: 2 hours of daily patching with near activities
Number of subjects: 64

Group type: COMPARATOR
Intervention: 2 hours of daily patching without near activities
Number of subjects: 64
Study: 12206590

Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Group therapy (GT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Individual systematic desensitization (SD)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Reference group (no specialist treatment)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control subgroup (observation for 3 years)
Number of subjects: 65
Study: 10498596

Group type: EXPERIMENTAL
Intervention: GI5402 (100 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8951261

Group type: EXPERIMENTAL
Intervention: HIV‐1-infected children
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: AIDS-opportunistic infection group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Infected-other group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reverter children
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control children
Number of subjects: 32
Study: 1837425

Group type: EXPERIMENTAL
Intervention: Sub-anaesthetic dose of propofol
Number of subjects: 53

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 53
Study: 6353078

Group type: EXPERIMENTAL
Intervention: Digitalis treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no digitalis)
Number of subjects: 120
Study: 31930894

Group type: EXPERIMENTAL
Intervention: Combined treatment (penetrating acupuncture + kinesiotherapy)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Penetrating acupuncture
Number of subjects: 105

Group type: COMPARATOR
Intervention: Kinesiotherapy
Number of subjects: 105
Study: 29306479

Group type: EXPERIMENTAL
Intervention: serelaxin
Number of subjects: 1161
Study: 26892215

Group type: EXPERIMENTAL
Intervention: Caregiver oral health knowledge
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: Caregiver oral health behavior
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: Improved caregiver behavior score
Number of subjects: 992
Study: 25096386

Group type: EXPERIMENTAL
Intervention: Drain antisepsis (chlorhexidine disc dressing and sodium hypochlorite irrigation)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard drain care (control)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Colonized sides (tubing or fluid)
Number of subjects: 202
Study: 21632437

Group type: EXPERIMENTAL
Intervention: Healthy for Life Program (HELP) intervention
Number of subjects: 76
Study: 20947884

Group type: EXPERIMENTAL
Intervention: Visilizumab 5μg/kg intravenously on days 1 and 2
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 18295692

Group type: EXPERIMENTAL
Intervention: Epirubicin-iodized oil emulsions with nonionic contrast medium (experimental group)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Epirubicin-iodized oil emulsions with ionic contrast medium (control group)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Comparison of tumor grades between groups
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Patient survival
Number of subjects: 197
Study: 16499887

Group type: EXPERIMENTAL
Intervention: Haloperidol (2.5 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 14530475

Group type: COMPARATOR
Intervention: (123)I‐MIBG myocardial scintigraphy in group C
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: (123)I‐MIBG myocardial scintigraphy in groups A, B, and C
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: (123)I‐MIBG myocardial scintigraphy in group A
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: (123)I‐MIBG myocardial scintigraphy in group B
Number of subjects: 46
Study: 11052840

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Rotablation
Number of subjects: 502
Study: 8552791

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study: 1373033

Group type: EXPERIMENTAL
Intervention: Instructor-designed note cards
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-designed note cards
Number of subjects: 0
Study: 6849275

Group type: EXPERIMENTAL
Intervention: Weighed food intake recorded on tape recorders
Number of subjects: 18

Group type: COMPARATOR
Intervention: Estimated food intake recorded in small notebooks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1-day dietary record (both methods)
Number of subjects: 18
Study: 31912673

Group type: EXPERIMENTAL
Intervention: Carboplatin and pegylated liposomal doxorubicin (CD)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel (CP)
Number of subjects: 432
Study: 30736376

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 28864865

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25702958

Group type: EXPERIMENTAL
Intervention: High dairy protein (HP-D, >1.2 g of protein/kg body weight/d; ∼27 g/d dairy protein)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: High soy protein (HP-S, >1.2 g of protein/kg body weight/d; ∼27 g/d soy protein)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Usual protein intake (UP, <1.2 g of protein/kg body weight/d)
Number of subjects: 179
Study: 23688276

Group type: EXPERIMENTAL
Intervention: Ospexin®
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MPI Cephalexin® tablet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MPI Cephalexin® capsule
Number of subjects: 24